MHRA and NICE Seek Evidence on Digital Mental Health Technologies Programme

A survey running from 5 November 2026 to 26 February 2027 will assess the use and impact of Phase 1 resources.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a call for evidence on resources produced by the Wellcome-funded Digital Mental Health Technologies (DMHT) programme. The survey opened on 5 November 2026 and is scheduled to close on 26 February 2027.

The agencies are seeking feedback from developers and manufacturers of digital mental health technologies, healthcare professionals, researchers, policymakers, regulators, people with lived experience of mental health conditions, carers and members of the public.

According to MHRA and NICE, the survey is part of the programme’s Phase 1 evaluation. It aims to establish how the resources have been received and used across the sector. The agencies are particularly interested in whether the materials have affected users’ knowledge, confidence, decision-making and professional practice.

The resources were created to support the safe development, regulation, evaluation and adoption of digital mental health technologies, including mental health apps and other digital tools. Results from the survey will be used to judge whether Phase 1 outputs met their intended objectives and to inform the direction of Phase 2.

MHRA and NICE are encouraging stakeholders to respond whether they have used the resources extensively, minimally or not at all. They say the feedback will help identify strengths, point to areas for improvement and shape future work intended to improve the safety and effectiveness of digital mental health technologies.

SM

Sonia Marchetti

Sonia Marchetti covers home blood pressure monitors, digital thermometers, and pulse oximeters as a home health devices analyst focused on product selection and use boundaries. Her evidence framework examines cuff fit, measurement repeatability, thermometer placement, battery behavior, and the intended scope of ISO 81060-2 for automated blood pressure validation without assuming any device has passed it. She helps private label managers, pharmacy buyers, and quality teams compare sample evidence, labeling claims, and maintenance needs while leaving individual readings and clinical decisions to qualified care professionals.